Analysis of advanced glycation end products in the DHS Mind Study

Jeremy N. Adams, Susan E. Martelle, Laura M. Raffield, Barry I. Freedman, Carl D. Langefeld, Fang Chi Hsu, Joseph A Maldjian, Jeff D. Williamson, Christina E. Hugenschmidt, J. Jeffery Carr, Amanda J. Cox, Donald W. Bowden

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims Human studies of links between advanced glycation end-products (AGEs) and disease phenotypes are less common than studies of animal and cell models. Here, we examined the association of total AGEs with diabetes risk factors in a predominately type 2 diabetes (T2D) affected cohort. Methods AGEs were measured using an enzyme linked immunosorbant assay in 816 individuals from the DHS Mind Study (n = 709 T2D affected), and association analyses were completed. Results Total AGEs were associated with estimated glomerular filtration rate (p = 0.0054; β = - 0.1291) and coronary artery calcification (p = 0.0352; β = 1.1489) in the entire cohort. No significant associations were observed when individuals with T2D were analyzed separately. In individuals without T2D, increased circulating AGEs were associated with increased BMI (p = 0.02, β = 0.138), low density lipoproteins (p = 0.046, β = 17.07) and triglycerides (p = 0.0004, β = 0.125), and decreased carotid artery calcification (p = 0.0004, β = - 1.2632) and estimated glomerular filtration rate (p = 0.0018, β = - 0.1405). Strong trends were also observed for an association between AGEs and poorer cognitive performance on the digit symbol substitution test (p = 0.046, β = - 6.64) and decreased grey matter volume (p = 0.037, β = - 14.87). Conclusions AGEs may play an important role in a number of phenotypes and diseases, although not necessarily in interindividual variation in people with T2D. Further evaluation of specific AGE molecules may shed more light on these relationships.

Original languageEnglish (US)
Pages (from-to)262-268
Number of pages7
JournalJournal of Diabetes and its Complications
Volume30
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Advanced Glycosylation End Products
Type 2 Diabetes Mellitus
Glomerular Filtration Rate
Phenotype
LDL Lipoproteins
Carotid Arteries
Coronary Vessels
Triglycerides
Animal Models
Enzymes

Keywords

  • Advanced glycation end products
  • Cardiovascular disease
  • Cognition
  • Grey matter volume
  • Neuroimaging
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Adams, J. N., Martelle, S. E., Raffield, L. M., Freedman, B. I., Langefeld, C. D., Hsu, F. C., ... Bowden, D. W. (2016). Analysis of advanced glycation end products in the DHS Mind Study. Journal of Diabetes and its Complications, 30(2), 262-268. https://doi.org/10.1016/j.jdiacomp.2015.11.025

Analysis of advanced glycation end products in the DHS Mind Study. / Adams, Jeremy N.; Martelle, Susan E.; Raffield, Laura M.; Freedman, Barry I.; Langefeld, Carl D.; Hsu, Fang Chi; Maldjian, Joseph A; Williamson, Jeff D.; Hugenschmidt, Christina E.; Carr, J. Jeffery; Cox, Amanda J.; Bowden, Donald W.

In: Journal of Diabetes and its Complications, Vol. 30, No. 2, 01.03.2016, p. 262-268.

Research output: Contribution to journalArticle

Adams, JN, Martelle, SE, Raffield, LM, Freedman, BI, Langefeld, CD, Hsu, FC, Maldjian, JA, Williamson, JD, Hugenschmidt, CE, Carr, JJ, Cox, AJ & Bowden, DW 2016, 'Analysis of advanced glycation end products in the DHS Mind Study', Journal of Diabetes and its Complications, vol. 30, no. 2, pp. 262-268. https://doi.org/10.1016/j.jdiacomp.2015.11.025
Adams JN, Martelle SE, Raffield LM, Freedman BI, Langefeld CD, Hsu FC et al. Analysis of advanced glycation end products in the DHS Mind Study. Journal of Diabetes and its Complications. 2016 Mar 1;30(2):262-268. https://doi.org/10.1016/j.jdiacomp.2015.11.025
Adams, Jeremy N. ; Martelle, Susan E. ; Raffield, Laura M. ; Freedman, Barry I. ; Langefeld, Carl D. ; Hsu, Fang Chi ; Maldjian, Joseph A ; Williamson, Jeff D. ; Hugenschmidt, Christina E. ; Carr, J. Jeffery ; Cox, Amanda J. ; Bowden, Donald W. / Analysis of advanced glycation end products in the DHS Mind Study. In: Journal of Diabetes and its Complications. 2016 ; Vol. 30, No. 2. pp. 262-268.
@article{698fa42183674df0a9613f32ce8e455c,
title = "Analysis of advanced glycation end products in the DHS Mind Study",
abstract = "Aims Human studies of links between advanced glycation end-products (AGEs) and disease phenotypes are less common than studies of animal and cell models. Here, we examined the association of total AGEs with diabetes risk factors in a predominately type 2 diabetes (T2D) affected cohort. Methods AGEs were measured using an enzyme linked immunosorbant assay in 816 individuals from the DHS Mind Study (n = 709 T2D affected), and association analyses were completed. Results Total AGEs were associated with estimated glomerular filtration rate (p = 0.0054; β = - 0.1291) and coronary artery calcification (p = 0.0352; β = 1.1489) in the entire cohort. No significant associations were observed when individuals with T2D were analyzed separately. In individuals without T2D, increased circulating AGEs were associated with increased BMI (p = 0.02, β = 0.138), low density lipoproteins (p = 0.046, β = 17.07) and triglycerides (p = 0.0004, β = 0.125), and decreased carotid artery calcification (p = 0.0004, β = - 1.2632) and estimated glomerular filtration rate (p = 0.0018, β = - 0.1405). Strong trends were also observed for an association between AGEs and poorer cognitive performance on the digit symbol substitution test (p = 0.046, β = - 6.64) and decreased grey matter volume (p = 0.037, β = - 14.87). Conclusions AGEs may play an important role in a number of phenotypes and diseases, although not necessarily in interindividual variation in people with T2D. Further evaluation of specific AGE molecules may shed more light on these relationships.",
keywords = "Advanced glycation end products, Cardiovascular disease, Cognition, Grey matter volume, Neuroimaging, Type 2 diabetes",
author = "Adams, {Jeremy N.} and Martelle, {Susan E.} and Raffield, {Laura M.} and Freedman, {Barry I.} and Langefeld, {Carl D.} and Hsu, {Fang Chi} and Maldjian, {Joseph A} and Williamson, {Jeff D.} and Hugenschmidt, {Christina E.} and Carr, {J. Jeffery} and Cox, {Amanda J.} and Bowden, {Donald W.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.jdiacomp.2015.11.025",
language = "English (US)",
volume = "30",
pages = "262--268",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Analysis of advanced glycation end products in the DHS Mind Study

AU - Adams, Jeremy N.

AU - Martelle, Susan E.

AU - Raffield, Laura M.

AU - Freedman, Barry I.

AU - Langefeld, Carl D.

AU - Hsu, Fang Chi

AU - Maldjian, Joseph A

AU - Williamson, Jeff D.

AU - Hugenschmidt, Christina E.

AU - Carr, J. Jeffery

AU - Cox, Amanda J.

AU - Bowden, Donald W.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aims Human studies of links between advanced glycation end-products (AGEs) and disease phenotypes are less common than studies of animal and cell models. Here, we examined the association of total AGEs with diabetes risk factors in a predominately type 2 diabetes (T2D) affected cohort. Methods AGEs were measured using an enzyme linked immunosorbant assay in 816 individuals from the DHS Mind Study (n = 709 T2D affected), and association analyses were completed. Results Total AGEs were associated with estimated glomerular filtration rate (p = 0.0054; β = - 0.1291) and coronary artery calcification (p = 0.0352; β = 1.1489) in the entire cohort. No significant associations were observed when individuals with T2D were analyzed separately. In individuals without T2D, increased circulating AGEs were associated with increased BMI (p = 0.02, β = 0.138), low density lipoproteins (p = 0.046, β = 17.07) and triglycerides (p = 0.0004, β = 0.125), and decreased carotid artery calcification (p = 0.0004, β = - 1.2632) and estimated glomerular filtration rate (p = 0.0018, β = - 0.1405). Strong trends were also observed for an association between AGEs and poorer cognitive performance on the digit symbol substitution test (p = 0.046, β = - 6.64) and decreased grey matter volume (p = 0.037, β = - 14.87). Conclusions AGEs may play an important role in a number of phenotypes and diseases, although not necessarily in interindividual variation in people with T2D. Further evaluation of specific AGE molecules may shed more light on these relationships.

AB - Aims Human studies of links between advanced glycation end-products (AGEs) and disease phenotypes are less common than studies of animal and cell models. Here, we examined the association of total AGEs with diabetes risk factors in a predominately type 2 diabetes (T2D) affected cohort. Methods AGEs were measured using an enzyme linked immunosorbant assay in 816 individuals from the DHS Mind Study (n = 709 T2D affected), and association analyses were completed. Results Total AGEs were associated with estimated glomerular filtration rate (p = 0.0054; β = - 0.1291) and coronary artery calcification (p = 0.0352; β = 1.1489) in the entire cohort. No significant associations were observed when individuals with T2D were analyzed separately. In individuals without T2D, increased circulating AGEs were associated with increased BMI (p = 0.02, β = 0.138), low density lipoproteins (p = 0.046, β = 17.07) and triglycerides (p = 0.0004, β = 0.125), and decreased carotid artery calcification (p = 0.0004, β = - 1.2632) and estimated glomerular filtration rate (p = 0.0018, β = - 0.1405). Strong trends were also observed for an association between AGEs and poorer cognitive performance on the digit symbol substitution test (p = 0.046, β = - 6.64) and decreased grey matter volume (p = 0.037, β = - 14.87). Conclusions AGEs may play an important role in a number of phenotypes and diseases, although not necessarily in interindividual variation in people with T2D. Further evaluation of specific AGE molecules may shed more light on these relationships.

KW - Advanced glycation end products

KW - Cardiovascular disease

KW - Cognition

KW - Grey matter volume

KW - Neuroimaging

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84953341191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953341191&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2015.11.025

DO - 10.1016/j.jdiacomp.2015.11.025

M3 - Article

VL - 30

SP - 262

EP - 268

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 2

ER -